Advised a pharmaceutical manufacturer on a $90 million recapitalization, comprising $65 million in refinanced debt and $25 million in preferred equity. The preferred equity component freed approximately $22 million for a distribution to the company's owners, while structuring the transaction to comply with Medicaid and Medicare regulations.